JP2004520329A5 - - Google Patents

Download PDF

Info

Publication number
JP2004520329A5
JP2004520329A5 JP2002554108A JP2002554108A JP2004520329A5 JP 2004520329 A5 JP2004520329 A5 JP 2004520329A5 JP 2002554108 A JP2002554108 A JP 2002554108A JP 2002554108 A JP2002554108 A JP 2002554108A JP 2004520329 A5 JP2004520329 A5 JP 2004520329A5
Authority
JP
Japan
Prior art keywords
alkyl
ring
group
atoms
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002554108A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004520329A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/049550 external-priority patent/WO2002053158A1/en
Publication of JP2004520329A publication Critical patent/JP2004520329A/ja
Publication of JP2004520329A5 publication Critical patent/JP2004520329A5/ja
Pending legal-status Critical Current

Links

JP2002554108A 2000-12-29 2001-12-28 緑内障ibの治療方法 Pending JP2004520329A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25942600P 2000-12-29 2000-12-29
US29625701P 2001-06-06 2001-06-06
US30741801P 2001-07-24 2001-07-24
PCT/US2001/049550 WO2002053158A1 (en) 2000-12-29 2001-12-28 Method for treating glaucoma ib

Publications (2)

Publication Number Publication Date
JP2004520329A JP2004520329A (ja) 2004-07-08
JP2004520329A5 true JP2004520329A5 (enExample) 2005-12-22

Family

ID=27401231

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002554108A Pending JP2004520329A (ja) 2000-12-29 2001-12-28 緑内障ibの治療方法

Country Status (9)

Country Link
US (1) US7432254B2 (enExample)
EP (1) EP1353669B1 (enExample)
JP (1) JP2004520329A (enExample)
AT (1) ATE369856T1 (enExample)
AU (1) AU2002241670B2 (enExample)
CA (1) CA2433346A1 (enExample)
DE (1) DE60130030T2 (enExample)
MX (1) MXPA03005922A (enExample)
WO (1) WO2002053158A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1257272A4 (en) * 2000-02-23 2004-12-15 Alteon Inc THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISEASES RELATED TO PROTEIN AGING
EP2085086A3 (en) * 2000-07-13 2009-11-25 Synvista Therapeutics, Inc. Method for treating congestive heart failure or diabetic nephropathy
US7049333B2 (en) 2002-06-04 2006-05-23 Sanofi-Aventis Deutschland Gmbh Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
CN100349881C (zh) * 2003-04-02 2007-11-21 深圳市东阳光实业发展有限公司 取代五元氮杂环盐类化合物及其治疗蛋白老化相关疾病的用途
US20050014747A1 (en) * 2003-04-18 2005-01-20 Emily Reinhard Dihydrothiazine prodrugs of thiazolium agents
PL1660457T3 (pl) * 2003-08-26 2012-05-31 Ecole Polytechnique Fed Lausanne Epfl Ciecze jonowe bazujące na solach imidazoliowych zawierających nitrylową grupę funkcyjną
WO2005097766A1 (en) 2004-03-31 2005-10-20 Lexicon Genetics, Inc. 2-aminomethylthiazole-5-carboxamides as protein kinase modulators
DE602005024274D1 (de) 2004-07-16 2010-12-02 Sunesis Pharmaceuticals Inc Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
EP1917251B1 (de) 2005-08-21 2013-04-03 Abbott GmbH & Co. KG 5-ring-heteroaromaten-verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2571529A2 (en) 2010-05-14 2013-03-27 Mallinckrodt LLC Functional, cross-linked nanostructures for tandem optical imaging and therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ200429A (en) * 1981-04-30 1984-10-19 Smith & Nephew Ass Applicator for placing pharmaceutically active agent in contact with moist surface,e.g.,eye
US5140048A (en) * 1984-03-19 1992-08-18 The Rockefeller University Inhibitors of nonenzymatic cross-linking
US5017696A (en) * 1987-09-17 1991-05-21 The Rockefeller University Advanced glycosylation end products and associated methods
EP0458589B1 (en) * 1990-05-22 1995-01-18 R-Tech Ueno Ltd. Treatment of ocular hypertension with an ocular synergistic combination
NZ239161A (en) * 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
US5153205A (en) * 1990-10-01 1992-10-06 Merck & Co., Inc. Method to reduce introacular pressure without causing miosis
US5300031A (en) * 1991-06-07 1994-04-05 Liebel-Flarsheim Company Apparatus for injecting fluid into animals and disposable front loadable syringe therefor
NO315930B1 (no) 1995-01-18 2003-11-17 Picower Inst For Medical Res T Anvendelse av tiazoliumforbindelser ved fremstilling av farmasöytiske preparater, preparater som inneholder forbindelsene, samt nyetiazoliumforbindelser
US5656261A (en) 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
EP0808163B1 (en) * 1995-01-18 2003-07-23 Alteon, Inc. Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5854000A (en) * 1995-11-15 1998-12-29 Alteon Inc. Methods for measurement predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
US6121300A (en) * 1998-11-10 2000-09-19 Wagle; Dilip R. Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts
CA2448294A1 (en) * 2001-05-30 2002-12-05 Alteon Inc. Method for treating fibrotic diseases or other indications vi
JP2004532249A (ja) * 2001-05-30 2004-10-21 アルテオン インコーポレイテッド 緑内障viの治療方法
US6806268B2 (en) * 2001-05-30 2004-10-19 Alteon, Inc. Method for treating glaucoma V

Similar Documents

Publication Publication Date Title
RU2412192C2 (ru) Сульфонамидтиазолпиридиновые производные как активаторы глюкокиназы, пригодные для лечения диабета типа 2
RU2344128C2 (ru) Бензилпиридазиноны как ингибиторы обратной транскриптазы
JP2004504348A5 (enExample)
JP2006515339A5 (enExample)
US20030027820A1 (en) Method for treating fibrotic diseases or other indications V
JP2006513265A5 (enExample)
RU2006107785A (ru) 2, 4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
CA2361057A1 (en) Quinoline derivatives and quinazoline derivatives
BRPI0408962A (pt) inibidores sulfonamidas heterocìclicos contendo flúor- e trifluoroalquila da produção de beta amilóide e seus derivados
JP2005537312A5 (enExample)
ATE384052T1 (de) Pyrimidin-2-on-verbindungen und ihre verwendung als dopamin-d3-rezeptorliganden
JP2005511605A5 (enExample)
BR0313923A (pt) Derivados de 3-(sulfonamidoetil)-indol para uso como miméticos de glicocorticóide no tratamento de doenças inflamatórias, alérgicas e proliferativas
JP2004528334A5 (enExample)
KR930023360A (ko) 아릴기-또는 방향족헤테로시클릭기-치환된 아미노퀴놀론 유도체 및 항-hiv제
CA2636985A1 (en) Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents
WO2010083975A1 (en) Combinations comprising methotrexate and dhodh inhibitors
BR0313407A (pt) Novo uso de derivados de benzotiazol
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
IE880893L (en) 4-£4-£4-£4-££2-(2,4-Difluorophenyl)-2-(1H-azolylmethyl)-1,3-¹dioxolan-4-yl|methoxy|phenyl|-1-piperazinyl|phenyl|triazolon¹es
JP2004521150A5 (enExample)
RU2004103475A (ru) Производные арил-или гетероарилазолилкарбинолов для лечения недержания мочи
RU2007103831A (ru) Производные пиразола
CA2375671A1 (en) 4-phenyl-pyrimidine derivatives
TNSN05080A1 (en) NOVEL ANTIMYCOBACTERIAL COMPOUNDS (as filed) AND PYRROLE DERIVATIVES AS ANTIMYCOBACTERIAL COMPOUNDS (as published)